Healthcare Industry News: Ortec International
News Release - May 11, 2012
InVivo Therapeutics Adds Senior Leadership in Manufacturing and Cell ResearchJack Harvey and Celina Chang Join InVivo from Pervasis Therapeutics
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today the appointment of Jack Harvey as Senior Director of Manufacturing and Celina Chang as Senior Scientist as the Company ramps up preparations for a human clinical trial and begins to expand its product portfolio to other nervous system conditions.
Mr. Harvey will lead InVivo Therapeutics’ production of GMP polymer-based biomaterial technologies. Leveraging his seven years as the Director of Manufacturing at Pervasis Therapeutics, Inc., where he led combination biomaterial and cell therapy products through the FDA, Mr. Harvey will lend his knowledge to InVivo’s existing and future product pipeline. He will manage contracted and internal resources as well as Chemistry, Manufacturing and Control (CMC) development and manufacturing scale up. Mr. Harvey received his B.A. in biology from Harvard University and his M.P.H. Health Law from Boston University, School of Public Health.
“I’m excited to lead InVivo’s optimization of GMP biomaterial technology manufacturing processes,” Mr. Harvey said. “Spinal cord injury treatments are a very promising field, and I’m eager to provide patients with viable solutions for SCI and other nervous system disorders.”
Ms. Chang also previously worked at Pervasis as a scientist charged with process improvement for the company’s three-dimensional polymer matrix embedded with cells. At InVivo Therapeutics, Ms. Chang will lead the execution and review of experiments per GMP and GLP regulations, and undertake the analysis of various cultured cells for InVivo’s chronic spinal cord injury therapies. Prior to Pervasis, Ms. Chang worked at Ortec International, focused on advancing regenerative medicine and stem cell therapies. She holds a B.S. in biological engineering from Cornell University.
“We strongly believe that combination therapies are the future of chronic spinal cord injury, and I look forward to developing these technologies,” said Ms. Chang.
Said InVivo Chief Executive Officer Frank Reynolds, “InVivo is at an inflection point in our growth, and adding industry leaders like Jack and Celina will take our platform technology in new directions. We are creating a new paradigm in the treatment of neurological injuries, and as our team evolves we are pleased that we continue to attract the best in our business, enabling us to expedite our products to market.”
For more information about InVivo Therapeutics’ technologies, visit www.invivotherapeutics.com.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
Source: InVivo Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.